Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Sandford Smith Biography and Net Worth

Director of Cytokinetics

Sandford "Sandy" Smith joins the Cytokinetics Board of Directors with over 30 years of commercial, general management and corporate development experience in the biopharmaceutical and pharmaceutical industries. Mr. Smith is currently a Managing Director at Tullis Health Investors (THI), a family of funds focused on investments in emerging biopharmaceutical and other healthcare companies. Prior to joining THI, he served as Executive Vice President of Genzyme Corporation and President of their International Group, overseeing 45 offices around the world, and leading 1,300 employees. During his 15 years at Genzyme, Mr. Smith was responsible for the successful launch of 12 new products in multiple therapeutic categories, including rare genetic disease. From 1986 to 1996, Mr. Smith served as President and Chief Executive Officer and a Director of RepliGen Corporation, a publicly traded biotechnology company. Previously, Mr. Smith spent over ten years with Bristol-Myers Squibb Company where he held a number of general management positions in the international group, including Vice President of Corporate Development and Planning for the U.S. Pharmaceutical and Nutritional Group. Mr. Smith has served as Director on a number of boards of both public and private healthcare companies and currently serves as a Board member of Aegerion Pharmaceuticals and BIO Behavioral Diagnostics Corp, and is a member of the Board of Trustees of Brigham and Women's Hospital in Boston. Mr. Smith earned his B.Sc. degree from the University of Denver.

What is Sandford D. Smith's net worth?: The estimated net worth of Sandford D. Smith is at least $295,171.20 as of April 27th, 2021. Mr. Smith owns 5,920 shares of Cytokinetics stock worth more than $295,171 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Smith may own. Learn More about Sandford D. Smith's net worth.
How do I contact Sandford D. Smith?: The corporate mailing address for Mr. Smith and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Sandford D. Smith's contact information.
Has Sandford D. Smith been buying or selling shares of Cytokinetics?: Sandford D. Smith has not been actively trading shares of Cytokinetics in the last ninety days. Most recently, Sandford D. Smith sold 29,032 shares of the business's stock in a transaction on Friday, November 19th. The shares were sold at an average price of $41.21, for a transaction totalling $1,196,408.72. Learn More on Sandford D. Smith's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 43 times. They sold a total of 432,011 shares worth more than $27,490,574.11. The most recent insider tranaction occured on November, 18th when CEO Robert I Blum sold 5,000 shares worth more than $252,750.00. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 11/18/2024.

Sandford D. Smith Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2021	Sell	29,032	$41.21	$1,196,408.72
7/19/2021	Sell	11,965	$28.87	$345,429.55
4/27/2021	Sell	9,739	$27.76	$270,354.64	5,920
4/23/2021	Sell	5,000	$26.50	$132,500.00
4/15/2021	Sell	10,714	$25.23	$270,314.22
4/9/2021	Sell	27,582	$23.93	$660,037.26
7/15/2020	Sell	6,667	$29.00	$193,343.00	6,667
7/10/2020	Sell	6,667	$28.00	$186,676.00	6,667
7/8/2020	Sell	13,176	$26.51	$349,295.76	5,232
6/22/2020	Sell	10,000	$24.50	$245,000.00	5,000
6/17/2020	Sell	6,907	$23.00	$158,861.00	4,166
6/15/2020	Sell	6,666	$22.00	$146,652.00	6,666
6/12/2020	Sell	15,045	$21.38	$321,662.10	10,879

Sandford D. Smith Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $49.86

$49.65

$50.95

50 Day Range

MA: $53.86

$49.86

$58.62

2 Week Range

Now: $49.86

$30.68

$110.25

Volume

1,063,163 shs

Average Volume

1,256,900 shs

Market Capitalization

$5.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

This company will win the AI race

From Porter & Company | Ad